An example of an FDA approved RNAi based therapy by Alnylam Pharmaceuticals is OnpattroTM for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. This evidence concerns the gene TTR and polyneuropathy.